Targeting the host metabolome to reverse drug-induced epigenetic changes

靶向宿主代谢组以逆转药物诱导的表观遗传变化

基本信息

批准号：
10205016
负责人：
Drew Kiraly
金额：
$ 50.85万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10205016
关键词：
Affect Behavior Behavioral Binding Sites Brain Cells Chromatin Chromatin Structure Coupled DNA Data Dietary Supplementation Drug Controls Drug Utilization Drug usage Environment Enzymes Epigenetic Process Exposure to Gene Expression Genes Histones Intake Laboratories Literature Mass Spectrum Analysis Metabolic Metabolism Metabolite Interaction Nucleus Accumbens Pathologic Pattern Pharmaceutical Preparations Point Mutation Regulation Relapse Role Self Administration Serum Signal Transduction Specificity Substance Use Disorder Synaptic plasticity Targeted Research Technology Transgenic Mice Translational Research Withdrawal XCL1 gene behavioral response brain behavior cell growth regulation cofactor dietary restriction drug of abuse epigenetic regulation genetic manipulation histone modification metabolome metabolomics motivated behavior novel prevent protein complex

项目摘要

Project Summary Pathological substance use disorders are a set of devastating psychiatric conditions marked by a pattern of escalating and out of control drug intake and an often-persistent cycle of withdrawal and relapse. One of the critical questions for translational research on substance use disorders is how exposure to drugs of abuse leads to such persistent dysregulation in patterns of motivated behaviors. Long-lasting changes to chromatin structure underlie the persistent dysregulation of gene expression and behavior seen in substance use disorders. Regulation of chromatin structure requires the integration of a myriad of signals from the environment, and there is a robust literature demonstrating that levels of key metabolites and cofactors regulate chromatin dynamics. Notably, nearly all enzymes that modify histones or DNA utilize key metabolites as substrates or cofactors in their catalytic activity. Therefore, availability of key metabolites directly affects the ability of a cell to make alter chromatin structure. Our preliminary studies show that repeated exposure to drugs of abuse markedly alters the serum and brain metabolome. Many of the dysregulated metabolites are those known to be critical cofactors for the function of epigenetic writers and erasers. Parallel to this, genes involved in the regulation of cellular metabolism in the nucleus accumbens were markedly altered even after prolonged withdrawal. Taken together, these data identify the metabolome as a novel means to target epigenetic regulation in substance use disorders. Initial studies will utilize drug self-administration and reinstatement coupled with serum and brain metabolomics to further identify metabolites that correlate with drug intake and drug seeking. Subsequent studies will determine how manipulations of metabolite signaling alter behavioral response and brain epigenetics. Systemic manipulation of metabolites via dietary restriction or supplementation will clarify the role of these metabolites on behavior, and cell-specific gene manipulations of key metabolic enzymes will add specificity and clarity to observed effects. Metabolic manipulations will be coupled with cell-specific chromatin profiling via ATAC-sequencing, quantitative mass spectrometry to identify changes in histone modifications, and chromatin-associated protein complexes in order to examine the interaction of behavioral and epigenetic effects. Finally, we will utilize cutting edge transgenic mouse technology to create inducible point mutations in epigenetic writers/erasers at key metabolite binding sites to assess the effects on behavior and chromatin structure when enzyme-metabolite interactions are prevented. These studies will define a new field of research targeting metabolic regulation of chromatin in substance use disorders and will identify novel translational research targets that will markedly increase our understanding of epigenetic regulation in substance use disorders.

项目概要病理性物质使用障碍是一系列破坏性的精神疾病，其特征是药物摄入量不断增加且失控，以及经常持续的戒断和复发循环。中的一个物质使用障碍转化研究的关键问题是如何接触滥用药物导致动机行为模式持续失调。染色质的持久变化药物滥用中基因表达和行为持续失调的潜在结构失调。染色质结构的调节需要整合来自染色质的大量信号环境，并且有大量文献证明关键代谢物和辅因子的水平调节染色质动力学。值得注意的是，几乎所有修饰组蛋白或 DNA 的酶都利用关键代谢物作为其催化活性的底物或辅助因子。因此，关键代谢物的可用性直接影响细胞改变染色质结构的能力。我们的初步研究表明，反复接触药物滥用会显着改变血清和脑代谢组。许多失调的代谢物是已知是表观遗传写入器和擦除器功能的关键辅助因子。与此平行，涉及基因即使经过长时间的治疗，伏隔核细胞代谢的调节也发生了显着改变。撤回。综上所述，这些数据表明代谢组是一种靶向表观遗传的新方法物质使用障碍的监管。初步研究将利用药物自我给药和恢复结合血清和脑代谢组学，进一步鉴定与药物摄入和相关的代谢物寻求药物。后续研究将确定代谢信号传导如何改变行为反应和大脑表观遗传学。通过饮食限制或系统性地控制代谢物补充将阐明这些代谢物对行为的作用，以及细胞特异性基因操作关键代谢酶将增加观察到的效果的特异性和清晰度。代谢操纵将通过 ATAC 测序、定量质谱法结合细胞特异性染色质分析来识别组蛋白修饰和染色质相关蛋白复合物的变化，以检查行为和表观遗传效应的相互作用。最后，我们将利用最先进的转基因小鼠在关键代谢物结合位点的表观遗传写入器/擦除器中创建诱导点突变的技术评估当酶-代谢物相互作用被阻止时对行为和染色质结构的影响。这些研究将定义一个新的研究领域，针对物质使用中染色质的代谢调节疾病并将确定新的转化研究目标，这将显着增加我们对疾病的理解物质使用障碍的表观遗传调控。